MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (?)
Ratings Breakdown: 2 Hold Rating(s), 18 Buy Rating(s)
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $124.53 (53.02% upside)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Leerink SwannReiterated RatingOutperform$107.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Oppenheimer Holdings Inc.Reiterated RatingMarket Perform$99.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Barclays PLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Credit Suisse Group AGReiterated RatingBuy$103.00 -> $114.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Goldman Sachs Group Inc.Reiterated RatingBuy$126.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016WedbushReiterated RatingNeutral$108.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Jefferies GroupReiterated RatingBuy$120.00 -> $116.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016BMO Capital MarketsInitiated CoverageOutperform$99.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Robert W. BairdInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016Stifel NicolausBoost Price TargetBuy$105.00 -> $107.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016Bank of America Corp.Reiterated RatingBuy$165.00 -> $135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2015Raymond James Financial Inc.Reiterated RatingOutperform$157.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Deutsche Bank AGReiterated RatingBuy$160.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/4/2015Nomura Holdings Inc.Reiterated RatingBuy$163.00 -> $173.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/4/2015SunTrust Banks Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015Canaccord GenuityBoost Price TargetBuy$115.00 -> $150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2015Brean CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2015Citigroup Inc.Reiterated RatingBuy$94.00 -> $133.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2015Evercore ISIInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2014Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q215($0.53)($0.51)$218.16 million$250.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.53)($0.43)$201.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015Q414($0.59)($0.47)$189.01 million$230.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q214($0.41)($0.23)$159.70 million$191.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014($0.44)($0.01)$145.16 million$151.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2011($0.10)$0.14ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($2.51)($0.40)($0.94)
Q2 20166($4.02)($0.27)($2.11)
Q3 20166($0.63)($0.24)($0.46)
Q4 20165($0.67)($0.26)($0.53)
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.28)($0.28)($0.28)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)
Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateHeadline
06/30/16 03:07 PMNew Market Report: BioMarin Pharmaceutical Inc. (BMRN) - Financial and Strategic SWOT Analysis Review
06/30/16 10:46 AMBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Company Rating and Target Watch - Telanagana Press
06/30/16 10:46 AMBioMarin Pharmaceutical Inc. Stock Momentum Hits Weakness - CML News
06/29/16 01:24 PMBioMarin’s Guidance for 2016: The Inside Story -
06/29/16 11:10 AMBioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Taking a look at the Consensus Estimates from Analysts - Telanagana Press
06/29/16 11:10 AMBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Current Analyst Ratings - Fiscal Standard
06/27/16 02:33 PMMost important stocks of the day: BioMarin Pharmaceutical Inc.
06/25/16 02:51 PMMost important stocks of the day: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Twin County News
06/24/16 03:15 PMAfter Brexit, These Biotech Stocks Are Vulnerable To A Mighty Dollar -
06/22/16 07:40 AMSummit Therapeutics PLC (ADR) (NASDAQ:SMMT) Is Hot On Sarepta Therapeutics Inc (NASDAQ:SRPT)’s DMD Tail
06/22/16 07:40 AMDirector of BioMarin Pharmaceutical Inc (NASDAQ:BMRN), Lawlis V Bryan, sells 550 shares worth $45,524
06/20/16 03:49 PMBioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL - [at noodls] - SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII ...
06/17/16 11:25 AMBioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced -
06/17/16 10:50 AMNotable Analyst's Ranking Preview: CVS Health Corporation (NYSE:CVS) , BioMarin Pharmaceutical Inc. (NASDAQ ... - Street Updates
06/17/16 10:50 AMHC Stocks Highlights: Celgene Corporation (NASDAQ:CELG), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - share market updates (press release)
06/16/16 08:16 PMU.S. stocks suffer fifth straight loss, even as Fed holds rates steady
06/16/16 08:16 PMAAL, BMRN and CAVM stock couldn't wait for Thursday's trading to end
06/16/16 02:53 PMStocks Showing Momentum: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Rio Tinto plc (NYSE:RIO) - Beacon Chronicle
06/16/16 12:42 PMWhy BioMarin (BMRN) Stock Is Lower Today -
06/16/16 12:03 PMBioMarin: Overreaction? -
06/16/16 11:24 AMBioMarin Stock Stumbles On Trial Halt, But No New Issue -
06/16/16 07:16 AMReview of Price Trends: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) , Quest Diagnostics Incorporated (NYSE:DGX) - Street Updates
06/16/16 07:16 AMStock's Earnings Analysis Report: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), The Michaels Companies, Inc ... - Beacon Chronicle
06/14/16 02:50 PMAnalyst Opinion on these Stocks: Chimerix, Inc. (NASDAQ:CMRX), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Beacon Chronicle
06/14/16 02:50 PMReview of Price Trends: OraSure Technologies, Inc. (NASDAQ:OSUR) , BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Street Updates
06/13/16 10:53 AMCredit Suisse Cuts BioMarin Price Target As Company Gives Up Revenue For Profit
06/12/16 02:53 PMCan BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Keep Up with Analyst Expectations? - Investor Newswire
06/10/16 07:01 AMBIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/09/16 02:53 PMBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Fundamental Star Rating Report - CML News
06/09/16 12:40 PMBioMarin Pharmaceutical, Inc. – Value Analysis (NASDAQ:BMRN) : June 9, 2016 -
06/08/16 03:23 PMBest Stocks to Buy: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Columbia Pipeline Partners LP (NYSE:CPPL) - Beacon Chronicle
06/08/16 11:25 AMPrice Review of Stocks: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) , Incyte Corporation (NASDAQ:INCY) - Street Updates
06/08/16 07:25 AMBioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : June 8, 2016 -
06/06/16 02:46 PMBIOMARIN PHARMACEUTICAL INC. (NASDAQ:BMRN) Financial Condition Compared to S&P 500 - CML News
06/06/16 09:37 AMBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Update & Estimates - Stock Tick Tock
06/06/16 09:37 AMRhenman & Partners Asset Management Ab Increased Biomarin Pharmaceutical INC (NASDAQ:BMRN) by $5.90 ... - CCH Daily News
06/04/16 11:24 AMBioMarin Pharmaceutical Inc. (BMRN) Receives Buy Rating from Leerink Swann - Let Me Know About This
06/03/16 02:59 PMEarnings Expectations Overview: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Cemtrex Inc. (NASDAQ:CETX) - Beacon Chronicle
06/03/16 02:59 PMBioMarin Pharmaceutical Inc. (BMRN) Receives Overweight Rating from Barclays - Let Me Know About This
06/03/16 11:28 AMThere's Hope For BioMarin Beyond Kyndrisa - Benzinga
06/02/16 08:04 PM​In wake of another delay, Duchenne advocates brace for longer wait -
06/02/16 11:40 AMAnalyst Recommended Buy These Stocks: Pentair plc (NYSE:PNR), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Beacon Chronicle - Analyst Recommended Buy These Stocks: Pentair plc (NYSE:PNR), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Beacon ChronicleLast Trade: The Company closed its last session at $60.19 with the loss of -0.08%. The market capitalization of the company is $10.92 Billion, with the average Volume of 1.34 Million. The stock currently has its 52-Week High range of $69.65 and 52-week ...and more »
06/02/16 10:32 AMSarepta Stock Tumbles As Hopes For Muscular Dystrophy Drug Dim -
06/01/16 11:24 AMBioMarin Pharma (BMRN) Withdraws Kyndrisa MAA in Europe - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it has withdrawn its Kyndrisa (drisapersen) Marketing Authorization Application (MAA) from the European ...
06/01/16 11:24 AMAnalyst Downgrades: Nike Inc, Under Armour Inc, and BioMarin Pharmaceutical Inc. - The brokerage firm also slashed its price target to $60 from $69. As a result, Nike Inc is pointed 3.2% lower in electronic trading, after settling Tuesday at $55.22 -- down 11.6% in 2016. If the stock doesn't bounce back soon, another round of downgrades ...
06/01/16 11:24 AMBioMarin Withdraws Kyndrisa Marketing Application in EU - BioMarin Pharmaceutical Inc. BMRN announced that it has withdrawn a Marketing Authorisation Application (MAA) for Kyndrisa (drisapersen) from the EU, following discussions with the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
05/31/16 08:35 PMBioMarin Pharma (BMRN) Withdraws Kyndrisa MAA in Europe - StreetInsider.com - San Francisco Business Times (blog)BioMarin Pharma (BMRN) Withdraws Kyndrisa MAA in EuropeStreetInsider.comBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it has withdrawn its Kyndrisa (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 2016 Committee for ...BioMarin bags drisapersen developmentSeeking AlphaBioMarin's $700M bet becomes 'sucker punch' for rare disease patientsSan Francisco Business Times (blog)all 8 news articles »
05/31/16 08:35 PMStock Review and Earnings Check on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - HNN - Stock Review and Earnings Check on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)HNNCurrently, sell-side analysts are expecting BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report quarterly EPS of $-0.5. The company's next earnings report is expected to be published on or around 2016-08-01 for the period ending on 2016-06-30.
05/31/16 04:30 PMBioMarin to Stop Developing its Duchenne Muscle Disease Drug -
05/31/16 03:05 PM4:05 pm BioMarin withdraws market authorization application for Kyndrisa (drisapersen) in Europe -
About BioMarin Pharmaceutical

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BMRN
  • CUSIP: 09061G10
Key Metrics:
  • Previous Close: $77.80
  • 50 Day Moving Average: $84.00
  • 200 Day Moving Average: $85.12
  • P/E Ratio: N/A
  • P/E Growth: -1.03
  • Market Cap: $13.17B
  • Current Quarter EPS Consensus Estimate: $-3.02 EPS
Additional Links:
BioMarin Pharmaceutical (NASDAQ:BMRN) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha